WuXi AppTec (stock code: 603259.SH/2359. HK) provides integrated, end-to-end new drug research and production services for the global biopharmaceutical industry, with operating bases in Asia, Europe, North America, and other regions. Through its unique "CRDMO" and "CTDMO" business models, WuXi AppTec continuously lowers research and development thresholds, helps customers improve research and development efficiency, and brings more breakthrough treatment plans to patients. Its service scope covers chemical drug research and production, biological research, preclinical testing and clinical trial research and development, cell and gene therapy research and development, testing and production, and other fields. In 2023, WuXi AppTec was rated as ESG (Environmental, Social, and Governance) AA by MSCI. At present, the company's empowerment platform is carrying R&D innovation projects from over 6000 partners from more than 30 countries around the world, committed to bringing more new and good drugs to patients worldwide, and realizing the vision of "making the world without difficult drugs and difficult diseases" as soon as possible.

Wuxi XDC (stock code: 2268. HK) is a leading contract research, development, and manufacturing organization (CRDMO), focusing on the global ADC and broader bio coupling market. It is a pioneering CRDMO that provides integrated end-to-end services. The services are provided by state-of-the-art laboratories and manufacturing facilities located nearby, greatly reducing development time and costs. Our over 1000 skilled employees are spread across the global network, providing our clients with expert driven, high-quality, and accurate first time project execution. By providing a single source, open access platform with the most comprehensive capabilities and technologies, Wuxi XDC enables our biopharmaceutical partners to accelerate the development of innovative therapies, benefiting patients worldwide.

Anhui Zhongke Gengjiu Hospital is a provincial-level comprehensive hospital approved by the Anhui Provincial Health Commission, which integrates first aid, prevention, medical treatment, teaching, and scientific research. The hospital is located at No. 999 Huayuan Avenue, Baohe District (southeast corner of the intersection of Huizhou Avenue and Huayuan Avenue, next to Exit C of Gaowang Station on Hefei Metro Line 1). The total investment of the first phase of the hospital project is 1.6 billion yuan, with a construction area of 162000 square meters. It is planned to open 1200 beds, and currently 500 beds are open. The hospital started operating on December 26, 2021, and is a designated hospital for medical insurance for provincial and municipal employees, as well as urban and rural residents. It has also achieved direct settlement for cross provincial and cross regional medical treatment nationwide. In January 2022, the hospital was officially authorized to become the Clinical College of Anhui Medical University, and has signed medical consortium cooperation agreements with well-known tertiary hospitals in the province, such as the First Affiliated Hospital of the University of Science and Technology of China (Anhui Provincial Hospital), Anhui Cancer Hospital, and the First Affiliated Hospital of Anhui Medical University. In March 2023, the hospital officially joined the China-Japan Friendship Hospital National Telemedicine and Internet Diagnosis and Treatment Center, and became an alliance unit of "National Integrated Chinese and Western Medicine Diagnosis and Treatment Center". In December 2023, the hospital signed a strategic cooperation agreement with Anhui University of Traditional Chinese Medicine.

Yaoming Shengji is a CTDMO under WuXi AppTec that focuses on cell and gene therapy, committed to accelerating and revolutionizing the development, testing, manufacturing, and commercialization of cell therapy, gene therapy, and other high-end therapies. Yaoming Shengji can help global customers push more innovative therapies to the market as soon as possible, benefiting patients. Shanghai Yaoming Shengji Pharmaceutical Technology Co., Ltd. was established on September 14, 2020, with its enterprise address located at Building 40, No. 356 Zhengbo Road, Lingang New Area, China (Shanghai) Pilot Free Trade Zone. The industry it belongs to is technology promotion and application services, and its business scope includes general projects such as technical services, technology development, technology consulting, technology exchange, technology transfer, and technology promotion; Enterprise management; Information consulting services (excluding licensed information consulting services); Health consultation services (excluding diagnosis and treatment services); Technology import and export; Import and export of goods. (Except for projects that require approval according to law, business activities can be carried out independently based on the business license in accordance with the law) Licensed project: commissioned production of drugs. (Projects that require approval according to law can only be carried out after being approved by relevant departments. The specific business projects shall be subject to the approval documents or licenses issued by relevant departments.). The current operating status of Shanghai Yaoming Shengji Pharmaceutical Technology Co., Ltd. is in existence (in operation, open, registered).

Shanghai Siemens Medical Equipment Co., Ltd. (hereinafter referred to as "SSME") was established in 1992 and is a wholly-owned subsidiary of Siemens (China) Co., Ltd. At present, the company is committed to the research and development and production of computer tomography diagnostic equipment (CT), X-ray machine diagnostic equipment, and their components, and provides relevant customer services. It has been awarded the title of high-tech enterprise by the Shanghai Municipal Government. SSME is not only the medical imaging equipment manufacturing base that supplies the global market in Siemens medical business, but also one of the research and development centers for imaging equipment in Siemens medical business. The company has over 800 employees, including over 270 research and development personnel. SSME is located in the Shanghai International Medical Park (No. 278 Zhouzhu Road), covering an area of 100000 square meters, with various R&D and production areas covering over 35000 square meters and a total investment of over 300 million RMB. It is the largest R&D and manufacturing center of Siemens medical business in the Asia Pacific region and currently one of the largest high-tech enterprises in medical device R&D and production in Shanghai.

Yingke Medical Technology Co., Ltd. (referred to as Yingke Medical) is a high-tech manufacturing enterprise dedicated to the research and development, production, and marketing of medical device consumables. It was listed on the ChiNext board of the Shenzhen Stock Exchange in July 2017, with stock code 300677. It is one of the top 500 Chinese brands, one of the top 500 manufacturing enterprises in China, and one of the top 100 listed companies in 2021. Our business covers a series of products including medical consumables, health equipment, and physical therapy nursing. The product is widely used in medical institutions, elderly care institutions, household daily necessities, and other related industries. Yingke Medical products have been exported to over 120 countries and regions in the Americas, Europe, Asia, Africa, and Oceania, providing practical products and high-quality services to over 10000 customers worldwide.